Share

May 2021; 8 (3) ArticleOpen Access

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Sabine Tacke, Stefan Braune, Damiano M. Rovituso, Tjalf Ziemssen, Paul V. Lehmann, Heidi Dikow, Arnfin Bergmann, Stefanie Kuerten
First published March 11, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000980
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
785

Share

Article Information

vol. 8 no. 3 e980
DOI: 
https://doi.org/10.1212/NXI.0000000000000980
PubMed: 
33707177
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received July 23, 2020
  • Accepted in final form January 12, 2021
  • First Published March 11, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Sabine Tacke, MSc (sabine.tacke{at}fau.de),
    2. Stefan Braune, MD (sbraune{at}neurotransdata.com),
    3. Damiano M. Rovituso, PhD (damianorovituso{at}yahoo.de),
    4. Tjalf Ziemssen, MD (tjalf.ziemssen{at}uniklinikum-dresden.de),
    5. Paul V. Lehmann, MD (paul.lehmann{at}immunospot.com),
    6. Heidi Dikow, MSc (hdikow{at}neurotransdata.com),
    7. Arnfin Bergmann, MD (abergmann{at}neurotransdata.com) and
    8. Stefanie Kuerten, MD, PhD
  1. Sabine Tacke, MSc (sabine.tacke{at}fau.de),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stefan Braune, MD (sbraune{at}neurotransdata.com),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Biogen 2) NeuroTransData

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) NeuroTransData

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Damiano M. Rovituso, PhD (damianorovituso{at}yahoo.de),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Biorasi GmbH (CRO), CTA/CRA, >1 year (Apr 2019 - ongoing) (2) Uniklinik Würzburg, Postdoc, < 1 year (Dec 2017 - Jul 2018) (3) University of Würzburg, Postdoc, 1 year (Aug 2016 - Oct 2017) (employment related to this manuscript)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tjalf Ziemssen, MD (tjalf.ziemssen{at}uniklinikum-dresden.de),
    5. Scientific Advisory Boards:

    1. (1) Bayer Healthcare (2) Biogen Idec (3) Novartis (4) Merck Serono (5) Teva (6) Genzyme (7) Roche (8) Celgene; all commercial

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honorarium for all commercial entities (1) Bayer Healthcare (2) Biogen Idec (3) Sanofi Genzyme (4) Celgene (5) Roche (6) Novartis (7) Teva (8) Almirall (o) Merck

    Editorial Boards:

    1. (1) BMC Neurology, Section editor, demyelinating disorders, since 2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen Idec (2) Sanofi Genzyme (3) Novartis (4) Teva

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Paul V. Lehmann, MD (paul.lehmann{at}immunospot.com),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. I am co-inventor on an issued patent that uses B cell ELISPOT to diagnose Multiple Sclerosis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am the Founder and CEO of CTL, a company that focuses on ELISPOT-based immune diagnostic.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Heidi Dikow, MSc (hdikow{at}neurotransdata.com),
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NeuroTransData GmbH, Data Scientist, 3 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Arnfin Bergmann, MD (abergmann{at}neurotransdata.com) and
    8. Scientific Advisory Boards:

    1. (1) NeuroTransData GmbH

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis (2) Servier

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Stefanie Kuerten, MD, PhD
    9. Scientific Advisory Boards:

    1. (1) Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis (2) Sanofi Genzyme (3) Roche

    Editorial Boards:

    1. (1) International Journal of Molecular Sciences, Associate Editor, 2020-now (2) International Journal of Molecular Sciences, Special Issue Guest Editor, 2020 (3) BMC Neurology, Associate Editor, 2013-now

    Patents:

    1. (1) ELISPOT technology for the detection of autoimmune responses

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) NeuroTransData GmbH

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute of Anatomy and Cell Biology (S.T., D.M.R., S.K.), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany; NeuroTransData (S.B., H.D., A.B.), Neuburg an der Donau, Germany; Department of Neurology (T.Z.), Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; and Research and Development Department (P.V.L.), Cellular Technology Limited, Shaker Heights, OH.
  1. Correspondence
    Dr. Kuerten stefanie.kuerten{at}uni-bonn.de
View Full Text

Article usage

Article usage: March 2021 to August 2023

AbstractFullPdfSource
Mar 202179483145Highwire
Apr 20211124654Highwire
May 20211232756Highwire
Jun 20211618731Highwire
Jul 202178922Highwire
Aug 202125214Highwire
Sep 2021154313Highwire
Oct 202159326Highwire
Nov 2021283734Highwire
Dec 2021313622Highwire
Jan 2022417813Highwire
Feb 2022843814Highwire
Mar 20221133717Highwire
Apr 20221055017Highwire
May 20221272825Highwire
Jun 20221334824Highwire
Jul 20221157410Highwire
Aug 20221055618Highwire
Sep 20221285623Highwire
Oct 20221485326Highwire
Nov 2022706924Highwire
Dec 20221942625Highwire
Jan 20231624311Highwire
Feb 2023892711Highwire
Mar 2023613227Highwire
Apr 2023511610Highwire
May 2023432217Highwire
Jun 2023361717Highwire
Jul 2023542020Highwire
Aug 2023702219Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles